A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit
Community-acquired bacterial pneumonia (CABP) can lead to sepsis and is associated with high mortality rates in patients presenting with shock and/or respiratory failure and who require mechanical ventilation ...
Source: BMC Pulmonary Medicine - Category: Respiratory Medicine Authors: Pierre-Fran çois Laterre, Miguel Sánchez-García, Tom van der Poll, Olga de la Rosa, Kathy-Ann Cadogan, Eleuterio Lombardo and Bruno François Tags: Study protocol Source Type: research
More News: Bacterial Pneumonia | Intensive Care | Pneumonia | Respiratory Medicine | Stem Cell Therapy | Stem Cells | Study